Lazard Asset Management
VIR icon

Lazard Asset Management’s Vir Biotechnology VIR Stock Holding History

Lazard Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,799
Closed -$16K – 2486
2023
Q3 		$16K Buy
1,799
+542
+43% +$7.73K ﹤0.01% 2124
2023
Q2 		$30K Sell
1,257
-3,314
-73% -$83.2K ﹤0.01% 2004
2023
Q1 		$106K Buy
4,571
+214
+5% +$5.47K ﹤0.01% 1512
2022
Q4 		$110K Buy
+4,357
New +$107K ﹤0.01% 1496
2022
Q3 		– Sell
-3,943
Closed -$100K – 2569
2022
Q2 		$100K Buy
3,943
+280
+8% +$6.54K ﹤0.01% 1508
2022
Q1 		$94K Buy
3,663
+3,631
+11,347% +$108K ﹤0.01% 1421
2021
Q4 		$1K Sell
32
-1,218
-97% -$47.7K ﹤0.01% 2259
2021
Q3 		$54K Buy
+1,250
New +$54.1K ﹤0.01% 1656
2020
Q4 		– Sell
-242
Closed -$8K – 1997
2020
Q3 		$8K Buy
+242
New +$10.4K ﹤0.01% 1505

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Lazard Asset Management's VIR Position: Q4 2023 in Review

Lazard Asset Management sold out of Vir Biotechnology (VIR) in Q4 2023, closing a stake of 1,799 shares — an estimated $16K sold.

Lazard Asset Management first reported a position in VIR in Q3 2020 and held it in 9 quarters. The position peaked at $110K in Q4 2022. 206 funds tracked by Wall St. Rank hold VIR as of Q4 2023.

  • Lazard Asset Management reported no remaining Vir Biotechnology position as of Q4 2023 after selling out during the quarter.
  • Lazard Asset Management sold 1,799 Vir Biotechnology shares in Q4 2023, an estimated $16K.
  • Lazard Asset Management first reported a position in Vir Biotechnology in Q3 2020 and held it in 9 quarters.
  • Lazard Asset Management's Vir Biotechnology position peaked at $110K in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2023.

Based on Lazard Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.